Embecta Corp. (NASDAQ:EMBC) posted on Friday the second-quarter 2025 adjusted earnings of 70 cents per share, up from 67 cents a year ago, beating the consensus of 53 cents.
The diabetes care company reported sales of $259 million, beating the consensus of $253.94 million.
Revenues were down 9.8% on a reported basis, down 7.7% on an adjusted constant currency basis. U.S. revenues decreased 8.4% on both a reported and adjusted constant currency basis.
International revenues decreased 11.3% on a reported basis, and 7.0% on an adjusted constant currency basis.
Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Gross profit and margin were $164.1 million and 63.4%, compared to $185.4 million and 64.6% in the prior year. Adjusted gross profit and margin were $165.0 million and 63.7%, compared to $185.8 million and 64.7% a year ago.
Operating…



